Advaxis Inc. (ADXS) has entered into a licensing agreement with Knight Therapeutics Inc. (GUD.TO) to commercialize in Canada Advaxis’s product portfolio including its three lead drug candidates – axalimogene filolisbac for human papilloma virus (HPV)-associated cancers, ADXS-PSA for prostate cancer and ADXS-HER2 for HER2 expressing solid tumors.